Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
Focus of the Report: This report focuses on amniotic allograft (AA) for treatment or prevention of tendon and ligament injuries.
Technology Description: AA is prepared from sheets of amniotic membrane obtained shortly after caesarean delivery. For some products, amniotic membrane is de…
Retevmo (selpercatinib) is a novel oral highly selective RET inhibitor for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, and adult and pediatric patients 12 years of age and older with advanced or metastatic
Focus of Report: This report reviews clinical study abstracts and clinical practice guidelines addressing genetic testing for monogenic systemic autoinflammatory disorders (SAIDs). Autoinflammatory disorders that result from polygenic or multifactorial causes are not included in this report. At least 38 separate monogeni… Retevmo (selpercatinib) is a novel oral highly selective RET inhibitor indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). Focus of the Report: The use of minimally invasive sacroiliac joint (SIJ) fusion with the iFuse Implant System (SI-Bone Inc.) for the treatment of adults with SIJ dysfunction who have not experienced adequate relief from nonsurgical management (NSM). Technology Description: The iFuse i… Focus of the Report: This report focuses on matrix-induced autologous chondrocyte implantation (MACI) for the treatment of patients with chondral defects of the knee. Technology Description: MACI is a multi-stage procedure that involves 2 surgeries. During an initial arthroscopic surge… Enspryng (satralizumab) is interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. It is administered by subcutaneous injection. Focus of the Report: The use of deep brain stimulation (DBS) for treatment of refractory obsessive-compulsive disorder (OCD). Technology Description: DBS therapy uses mild electrical impulses to regulate electrical activity of neural circuits. Patients undergo surgery to implant a med… Focus of Report: This report reviews clinical study abstracts and clinical practice guidelines addressing expanded carrier screening. The report evaluates the analytical validity, clinical validity, and clinical utility of the FirstSightCRC test, a liquid biopsy test that detects and analyzes circulating tumor cells (CTCs) and is intended to predict the likelihood of having precancerous adenomatous polyps or colorectal cancer (CRC) in patients eligible for CRC screening.Genetic Testing for Monogenic Systemic Autoinflammatory Disorders (SAIDs)
Retevmo (Selpercatinib) for Non-Small Cell Lung Cancer (NSCLC)
Minimally Invasive Sacroiliac Joint Fusion Using Triangular Titanium Implants (iFuse Implant System, SI-Bone Inc.)
Matrix-Induced Autologous Chondrocyte Implantation (MACI) Procedure for Repair of Articular Cartilage of the Knee
Enspryng (Satralizumab-mwge) for Neuromyelitis Optica Spectrum Disorder
Deep Brain Stimulation for the Treatment of Refractory Obsessive-Compulsive Disorder
Expanded Carrier Screening
FirstSightCRC (CellMax Life)